Avalo Therapeutics (AVTX) vs Puma Biotechnology (PBYI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Puma Biotechnology (PBYI) has outperformed Avalo Therapeutics (AVTX) over the past year, gaining 44.2% versus a loss of 62.1%. Over five years, PBYI leads with a +118.3% price change compared with -99.9% for AVTX. Avalo Therapeutics is the larger company by market cap ($390.9 million vs $364.5 million), about 1.1 times the size, while Puma Biotechnology is growing revenue faster (-0.9% vs -86.6%).
Puma Biotechnology converts more of its revenue into profit, with a net margin of 13.6% versus -132642.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVTX | PBYI |
|---|---|---|
| Share price | $6.76 | $7.05 |
| Market cap | $390.88M | $364.47M |
| 1-day change | +0.15% | -0.98% |
| YTD return | -62.78% | +18.49% |
| 1-year return | -62.09% | +44.17% |
| 5-year return | -99.89% | +118.27% |
| P/E ratio (TTM) | — | 15.33 |
| Forward P/E | — | 20.14 |
| EPS (TTM) | $-2.26 | $0.46 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $59.00K | $228.37M |
| Revenue growth (YoY) | -86.62% | -0.91% |
| Net income (latest FY) | $-78.26M | $31.11M |
| Gross margin | — | 74.53% |
| Operating margin | -123601.69% | 16.33% |
| Net margin | -132642.37% | 13.62% |
| 52-week high | $24.27 | $11.50 |
| 52-week low | $6.53 | $4.84 |
| Distance from 52-week high | -72.15% | -38.70% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +414.79% | — |
| Average volume | 1.80M | 387.40K |
| Shares outstanding | 57.82M | 51.70M |
| Employees | 33 | 179 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PBYI has outperformed AVTX by 106.3 percentage points over the past year.
- Puma Biotechnology is more profitable, keeping 13.6 cents of every revenue dollar as net income versus -132642.4 cents for Avalo Therapeutics.
- Puma Biotechnology grew revenue faster in its latest fiscal year (-0.91% vs -86.62%).
About Avalo Therapeutics
AVTX stock →Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees
About Puma Biotechnology
PBYI stock →Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.
Health Care · Biotechnology: Pharmaceutical Preparations · 179 employees
AVTX vs PBYI FAQ
Which is bigger, Avalo Therapeutics or Puma Biotechnology?
Avalo Therapeutics (AVTX) is larger, with a market capitalization of $390.88M compared with $364.47M for Puma Biotechnology (PBYI).
Which stock has performed better over the past year, AVTX or PBYI?
PBYI returned +44.17% over the past 12 months, compared with -62.09% for AVTX (price return, excluding dividends). Past performance does not predict future results.
Are Avalo Therapeutics and Puma Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.